- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S4423
|
In vitro |
DMSO
: 100 mg/mL
(99.18 mM)
Ethanol : 100 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 1008.24 | Formula | C56H81NO15 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 155569-91-8 | -- | Storage of Stock Solutions |
|
|
| Synonyms | EMB, MK-244 | Smiles | CCC(C)C1OC2(CC3CC(C\C=C(C)\C(OC4CC(OC)C(OC5CC(OC)C(NC)C(C)O5)C(C)O4)C(C)/C=C/C=C/6COC7C(O)C(=CC(C(=O)O3)C67O)C)O2)C=CC1C.OC(=O)C8=CC=CC=C8 | ||
| Targets/IC50/Ki |
GABA transporter
|
References |
|
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06283524 | Not yet recruiting | Multiple Sclerosis |
Innodem Neurosciences |
March 18 2024 | -- |
| NCT05661266 | Recruiting | Multiple Sclerosis |
Innodem Neurosciences |
August 16 2023 | -- |
| NCT05498389 | Not yet recruiting | Metastatic Lung Non-Small Cell Carcinoma|Advanced Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|EGFR Mutation-Related Tumors |
Shanghai EpimAb Biotherapeutics Co. Ltd.|Labcorp Corporation of America Holdings Inc |
June 2023 | Phase 1|Phase 2 |
| NCT05607498 | Recruiting | Advanced/Metastatic Solid Tumors|Relapse/Refractory Lymphoma |
EpimAb Biotherapeutics (Suzhou)Co. Ltd. |
March 1 2023 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.